Rather & Kittrell’s Medifast MED Stock Holding History

Rather & Kittrell’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15	Closed	-$3K	–	204
2021 Q4	$3K	Buy	+15	New	+$3.1K	﹤0.01%	277

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Rather & Kittrell's MED Position: Q1 2022 in Review

Rather & Kittrell sold out of Medifast (MED) in Q1 2022, closing a stake of 15 shares — an estimated $3K sold.

Rather & Kittrell first reported a position in MED in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 288 funds tracked by Wall St. Rank hold MED as of Q1 2022.

Rather & Kittrell reported no remaining Medifast position as of Q1 2022 after selling out during the quarter.
Rather & Kittrell sold 15 Medifast shares in Q1 2022, an estimated $3K.
Rather & Kittrell first reported a position in Medifast in Q4 2021 and held it in 1 quarter.
Rather & Kittrell's Medifast position peaked at $3K in Q4 2021.
288 funds tracked by Wall St. Rank held Medifast as of Q1 2022.

Based on Rather & Kittrell's 13F filing for Q1 2022, filed 10 May 2022.